Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of aH5N1 vs FLUAD in adults and elderly, with and without immunosuppression
2011-003573-28Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated) in Influenza A H5N1 infection (H5N1) (2 arms), sponsored by Novartis. Primary endpoint: Primary immunogenicity endpoint. Started Jan 2014; status: completed.
02
Drugs
Influenza A virus A/Vietnam/1194/2004 (H5N1) antigen (formaldehyde inactivated)
03
Conditions
Influenza A H5N1 infection (H5N1)
Beyond the preview
Go deeper on 2011-003573-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003573-28.